Research

Hormonal

Metabolic syndrome, particularly through its components of obesity and insulin resistance, increases the risk of hepatocellular carcinoma (HCC) and worsens clinical outcomes, primarily mediated by the progression of nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) and cirrhosis.

If you have metabolic syndrome (obesity, high blood pressure, high blood sugar, or high triglycerides), your risk of liver cancer is significantly higher, even if you don't have hepatitis. This risk is driven by the progression of fatty liver to inflammation (NASH) and cirrhosis. Managing weight and insulin sensitivity is critical to reducing this risk.

GoodSupportsHIGH confidence
The majority of 'cryptogenic' HCC in the United States is attributed to nonalcoholic fatty liver disease (NAFLD), which is a hepatic manifestation of the metabolic syndrome... It is predicted that metabolic syndrome will lead to large increases in the incidence of HCC over the next decades.
Abby B. Siegel et al. · Cancer · 2009

Why this rating

Based on large prospective cohort studies and meta-analyses cited, though direct mechanistic causality in humans is still being defined.

Source

Metabolic syndrome and hepatocellular carcinoma

Abby B. Siegel et al. · Cancer · 2009

DOI 10.1002/cncr.24687

narrative_reviewCited 389×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →